An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Adicet Bio to Participate in 2023 Jefferies Biotech on the Bay Summit
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Adicet Bio, a clinical stage biotechnology company focused on allogeneic gamma delta T cell therapies for cancer, announced participation in the 2023 Jefferies Biotech on the Bay Summit from March 16-17, 2023. Representing the company will be Chen Schor, President and CEO, and Nick Harvey, CFO. Adicet Bio aims to enhance tumor targeting and anti-tumor immune response with its engineered gamma delta T cells. The team will hold one-on-one meetings at the conference, providing opportunities for deeper engagement with investors and partners. For more information, visit Adicet's website.
Positive
None.
Negative
None.
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, and Nick Harvey, Chief Financial Officer, will participate in the 2023 Jefferies Biotech on the Bay Summit being held March 16-17, 2023.
The Adicet Bio team will be available for one-on-one meetings throughout the conference. Please contact your sales representative at Jefferies to register for a meeting with the company.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs) and chimeric antigen adaptors (CAds), to enhance selective tumor targeting and facilitate innate and adaptive anti-tumor immune response for durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
